SS Innovations International Inc

SS Innovations International Inc(SSII)股票分析

$2.530

-0.049 (-1.94%)收盘时

Loading chart…
最高
2.650
开盘
2.580
成交量加权均价
2.56
成交量
39.22K
市值
—
最低
2.500
成交额
100.39K
企业价值/息税折旧摊销前利润(TTM)
-45.51

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset.

AI 分析 of SS Innovations International Inc (SSII)

卖出

Currently, SS Innovations International Inc (SSII) is not a good buy. The stock is trading at $2.53, which is significantly below its analyst price target of $7, indicating potential upside. However, the stock has shown a year-to-date change of -55.22% and a one-year change of -74.65%, reflecting substantial losses. Additionally, the RSI is at 31.583, suggesting the stock is oversold but also indicating a lack of momentum for recovery. The main risk is the company's negative net income, which was -2,661,350 USD in Q2 2026, highlighting ongoing financial struggles.

估值指标

SS Innovations International Inc(SSII)当前预期市盈率为 0.00,5 年平均预期市盈率为 0.00。

预期市盈率

严重低估
5 年均值 P/E
0.00
当前P/E
0.00
高估
0.00
低估
0.00

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
-14.94
当前EV/EBITDA
-45.51
高估
7.12
低估
-36.99

预期市销率

合理
5 年均值 P/S
3.18
当前P/S
6.79
高估
7.63
低估
-1.27

Alphio AI 对 SSII 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SSII

$8.47

情景价格

基

基准

基准 · 50%SSII

$7.13

情景价格

悲

悲观

悲观 · 25%SSII

$6.18

情景价格

事件时间线

2026-10-13 (ET)

09:00:00

SS Innovations Submits Response to FDA Additional Information Request

2026-07-14 (ET)

09:00:00

SS Innovations Appoints Sarah Romano as CFO

2026-05-05 (ET)

09:00:00

SS Innovations Surpasses 10,500 Cumulative Surgeries

2026-05-01 (ET)

16:30:00

SS Innovations Files $150M Mixed Securities Shelf

16:30:00

SS Innovations Files to Sell 5.02M Shares of Common Stock

资讯

SSII 常见问题 —— 由 Alphio AI 解答

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset. It operates in the Healthcare sector.

Currently, SS Innovations International Inc (SSII) is not a good buy. The stock is trading at $2.53, which is significantly below its analyst price target of $7, indicating potential upside. However, the stock has shown a year-to-date change of -55.22% and a one-year change of -74.65%, reflecting substantial losses. Additionally, the RSI is at 31.583, suggesting the stock is oversold but also indicating a lack of momentum for recovery. The main risk is the company's negative net income, which was -2,661,350 USD in Q2 2026, highlighting ongoing financial struggles.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易